“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study

Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study Publisher Pubmed

Salarvand F¹ ; Fatehi Z¹ ; Shahali M¹ ; Balighi K¹ ; Ghiasi M¹ ; Abedini R¹ ; Mahmoudi H¹ ; Tavakolpour S¹ ; Chamsdavatchi C¹ ; Daneshpazhooh M¹

Source: Dermatologic Therapy Published:2019

Abstract

[No abstract available]

Related Docs

View other Related Docs

1. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)

2. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)

3. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (18)

Hamid Reza Mahmoodi (13)

Other Related Docs

4. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)

5. Autoimmune Blistering Diseases Treated With Glucocorticoids: An International Study of Steroid-Induced Myopathy, Journal of the European Academy of Dermatology and Venereology (2025)

6. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)

7. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)

8. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)

9. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)

10. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)

11. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)

12. Pulmonary Nocardiosis in Pemphigus Vulgaris Patients From Tehran, Iran, Infectious Disorders - Drug Targets (2021)

13. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)

14. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)

15. Diagnosis and Management of Pemphigus: Recommendations of an International Panel of Experts, Journal of the American Academy of Dermatology (2020)

16. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)

17. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)

18. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)

19. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)

Style	Citing Format
MLA	Salarvand F, et al.. "“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study." Dermatologic Therapy, vol. 32, no. 2, 2019, pp. -.
APA	Salarvand F, Fatehi Z, Shahali M, Balighi K, Ghiasi M, Abedini R, Mahmoudi H, Tavakolpour S, Chamsdavatchi C, Daneshpazhooh M (2019). “Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study. Dermatologic Therapy, 32(2), -.
Chicago	Salarvand F, Fatehi Z, Shahali M, Balighi K, Ghiasi M, Abedini R, Mahmoudi H, Tavakolpour S, Chamsdavatchi C, Daneshpazhooh M. "“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study." Dermatologic Therapy 32, no. 2 (2019): -.
Harvard	Salarvand F et al. (2019) '“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study', Dermatologic Therapy, 32(2), pp. -.
Vancouver	Salarvand F, Fatehi Z, Shahali M, Balighi K, Ghiasi M, Abedini R, et al.. “Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study. Dermatologic Therapy. 2019;32(2):-.
BibTex	@article{ author = {Salarvand F and Fatehi Z and Shahali M and Balighi K and Ghiasi M and Abedini R and Mahmoudi H and Tavakolpour S and Chamsdavatchi C and Daneshpazhooh M}, title = {“Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study}, journal = {Dermatologic Therapy}, volume = {32}, number = {2}, pages = {-}, year = {2019} }
RIS	TY - JOUR AU - Salarvand F AU - Fatehi Z AU - Shahali M AU - Balighi K AU - Ghiasi M AU - Abedini R AU - Mahmoudi H AU - Tavakolpour S AU - Chamsdavatchi C AU - Daneshpazhooh M TI - “Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study JO - Dermatologic Therapy VL - 32 IS - 2 SP - EP - PY - 2019 ER -